About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/20/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/20/2021.

Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Rheumatoid Arthritis Refractory to Methotrexate

Clinicaltrials.gov identifier NCT03944096

Recruitment Status Recruiting

First Posted May 9, 2019

Last update posted May 23, 2019

Study Description

Brief summary:

In this 24-week, single center, randomized, double-blind study, the investigators will evaluate the efficacy and safety of fecal microbiota transplantation in patients with active rheumatoid arthritis refractory to methotrexate

  • Condition or Disease:Rheumatoid Arthritis
  • Intervention/Treatment: Procedure: FMT+MTX
  • Phase: Phase 2
Detailed Description

Rheumatoid arthritis (RA) is a chronic autoimmune disease, characterized by painful synovium inflammation, bony erosions, immune activation. Gut microbiota plays an important role in pathophysiology of RA. FMT(fecal microbiota transplantation) is the engraftment of microbiota from a healthy donor into a recipient to achieve restoration of the normal gut microbial community structure.This study evaluates the efficacy and safety of FMT with methotrexate in patients with active RA refractory to methotrexate Objectives: 1. To evaluate the efficacy of FMT with MTX for the treatment of signs and symptoms of RA in patients refractory to MTX. 2. To evaluate the safety of FMT with MTX for the treatment of signs and symptoms of RA in patients refractory to MTX DESIGN This is a Phase 2, randomized, 24-week, double-blind, parallel group study, and 30 patients with active RA refractory to MTX will be randomized in a 1:1 ratio to one of the following 2 parallel treatment arms: 1. FMT from healthy donor plus methotrexate 2. autologous FMT(from the participant himself/herself) plus methotrexate Escape: On week 16, all participants with inadequate response, defined as a <20% improvement of swollen and tender joint counts from baseline can switch type and dose of DMARDs. Endpoints : 1. Primary endpoint: ACR20 response rates at 16 weeks. 2. Secondary endpoint: 1)ACR50 and ACR70 response at 16, 24 weeks,ACR20 response at 24 weeks. 2)DAS 28 (CRP) and DAS 28 (ESR) at 16 and 24 weeks. 3) EULAR response rates at 16 and 24 weeks. 4) Health assessment questionnaire (HAQ) at 16 and 24 weeks. 5) Patient assessment of arthritis pain at 16 and 24 weeks. 6) Patient and physician global assessment of arthritis at 16 and 24 weeks

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 30 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: Efficacy and Safety of Faecal Microbiota Transplantation in Patients With Rheumatoid Arthritis Refractory to Methotrexate: a 24-week, Double-Blind, Randomised Trial
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: March 2020
  • Estimated Study Completion Date: July 2020
Arms and interventions
Arm Intervention/treatment
Experimental: FMT+MTX
FMT One FMT is performed at baseline by gastroscopic guidance. The same FMT is repeated 4 weeks later. The transplant consists of 50 g mixed feces obtained from 3-5 non-related healthy donors. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the recipient. Drug: Methotrexate (MTX) Weekly methotrexate
Procedure: FMT+MTX
FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
Placebo Comparator: autologous FMT+MTX
autologous FMT (the feces used in FMT is from participant themselves) One identical FMT is performed at baseline using gastroscopic guidance and is repeated 4 weeks later. The corresponding participant's feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 150 mL and its temperature will be 37 degrees celsius when infused into ileus of the participant himself or herself. Drug: Methotrexate (MTX) Weekly methotrexate
Procedure: FMT+MTX
FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
Outcome Measures
  • Primary Outcome Measures: 1. The American College of Rheumatology 20 (ACR20) response at 16 weeks [ Time Frame: week 16 ]
    The difference of ACR20 between Arm 1 (FMT+MTX) and Arm 2 (autologous FMT+MTX)
  • Secondary Outcome Measures: 1. The American College of Rheumatology 50/70 (ACR50/ACR70) response at 16 weeks [ Time Frame: week 16 ]
    The difference of ACR50/70 between Arm 1 (FMT+MTX) and Arm 2 (autologous FMT+MTX)
  • 2. The American College of Rheumatology 20/50/70 (ACR20/ACR50/ACR70) response at 24 weeks [ Time Frame: week 24 ]
    The difference of ACR20, ACR50 and ACR70 between Arm 1 (FMT+MTX) and Arm 2(autologous FMT+MTX) at week 24
  • 3. The Disease Activity Score-28 (DAS28) response at 16 weeks [ Time Frame: week 16 ]
    The change in DAS28 score from baseline to week 16 between Arm 1 (FMT+MTX) and Arm 2(autologous FMT+MTX). DAS28 = 0.56*SQRT(TJC28) + 0.28*SQRT(SJC28) + 0.36*ln(CRP + 1) + 0.014*GH + 0.96 TJC28: The number of tender joints (0-28). SJC28: The number of swollen joints (0-28). CRP: The C-Reactive Protein level (in mg/l). GH: The patient global health assessment (from 0=best to 100=worst). The 28 joint: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.
  • 4. The Disease Activity Score-28 (DAS28) response at 24 weeks [ Time Frame: week 24 ]
    The change in DAS28 score from baseline to week 24 between Arm 1 (FMT+MTX) and Arm 2(autologous FMT+MTX). DAS28 = 0.56*SQRT(TJC28) + 0.28*SQRT(SJC28) + 0.36*ln(CRP + 1) + 0.014*GH + 0.96 TJC28: The number of tender joints (0-28). SJC28: The number of swollen joints (0-28). CRP: The C-Reactive Protein level (in mg/l). GH: The patient global health assessment (from 0=best to 100=worst). The 28 joint: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints and the knees.
  • 5. The European League Against Rheumatism (EULAR) response at 16 weeks [ Time Frame: week 16 ]
    The difference of proportions of patients meeting EULAR response between Arm 1(FMT+MTX) and Arm 2 (autologous FMT+MTX) at week 16
  • 6. Health Assessment Questionnaire without Didability Index (HAQ-DI) at 16 weeks [ Time Frame: week 16 ]
    The change in HAQ-DI score from baseline to week 16 between Arm 1(FMT+MTX) and Arm 2 (autologous FMT+MTX). HAQ-DI is an index measuring the quality of life related to health, which includes 20 questions in terms of three categories: from 0 to 1: mild difficulties to moderate disability, from 1 to 2: disability moderate to severe, from 2 to 3: severe to very severe disability. The mean score is recorded as the result.
  • 7. Incidence of adverse events and sever adverse events (SAE) during the study [ Time Frame: week 24 ]
    Safety profile
Eligibility Criteria
  • Ages Eligible for Study: 18 to 65 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Age 18-65 years with informed consent

- Fulfill the 2010 ACR/EULAR classification criteria for rheumatoid arthritis

- Positive RF or anti-CCP antibody on screening

- Have active RA shown by swollen joint count(SJC)≥4 and tender joint count(TJC)≥4 and
ESR >28 mm/hr or C-reactive protein > 1.5 ULN

- Have received methotrexate for 3 months or longer and at a stable dose of 7.5 to 25
mg/week (extremes included) for at least four weeks prior to screening and willing to
continue on this regimen for the duration of the study.

- Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA

- If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or
prednisone equivalent and stable for at least four weeks prior to screening;

- If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable
dose for at least two weeks prior to screening;

- Female subjects must have a negative pregnancy test unless they are surgically sterile
or have been post-menopausal for at least one year (12 consecutive months without
menses);

- Women of childbearing potential must use a medically acceptable means of birth control
and agree to continue its use during the study and for at least four weeks after the
last dose of study drug. Sexually active men must agree to use a medically acceptable
form of contraception during the study and continue its use for at least 3 months
after the last dose of study drug; and

- Willing to suspend the use of other adjuvant treatment for the duration of the study
including acupuncture, massage, etc.

Exclusion Criteria:

- Pregnant, lactating or further fertility requirements

- History of any inflammatory rheumatological disorders other than RA;

- Previously received any biologic agents.

- Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background
methotrexate;

- Receipt of an intra-articular or parenteral corticosteroid injection within four weeks
prior to screening;

- Active or chronic infection, including HIV, HCV, HBV, tuberculosis.

- Malignancy or history of malignancy.

- Severe, progressive, or uncontrolled cardiac, pulmonary, renal, hepatic,
gastrointestinal, hematologic, metabolic, endocrine or neurologic disease

- unable to undergo colonoscopy.

Contacts and Locations
Contacts

Contact: Yue Li, MD +8618601309256 yuelee76@gmail.com

Locations

China, Beijing
Peking Union Medical College Hospital
Beijing

Sponsors and Collaborators

Peking Union Medical College Hospital

Investigators

Principal Investigator: Xuan Zhang, MD Peking Union Medical College Hospital

More Information
  • Responsible Party: Peking Union Medical College Hospital
  • ClinicalTrials.gov Identifier: NCT03944096 History of Changes
  • Other Study ID Numbers: FARM
  • First Posted: May 9, 2019 Key Record Dates
  • Last Update Posted: May 23, 2019
  • Last Verified: May 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Undecided
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Peking Union Medical College Hospital: fecal microbiota transplantation
    methotrexate
    rheumatoid arthritis
  • Additional relevant MeSH terms: Arthritis, Rheumatoid Arthritis